Suppr超能文献

超声增强急性动脉缺血溶栓治疗

Ultrasound enhanced thrombolysis in acute arterial ischemia.

作者信息

Tsivgoulis Georgios, Culp William C, Alexandrov Andrei V

机构信息

Comprehensive Stroke Center, Department of Neurology, University of Alabama at Birmingham, Suite 226, RWUHM, 1719 6th Avenue South, Birmingham, AL 35294, USA.

出版信息

Ultrasonics. 2008 Aug;48(4):303-11. doi: 10.1016/j.ultras.2007.11.008. Epub 2007 Dec 15.

Abstract

In vitro and animal studies have shown that thrombolysis with intravenous tissue plasminogen activator (tPA) can be enhanced with ultrasound. Ultrasound delivers mechanical pressure waves to the clot, thus exposing more thrombus surface to circulating drug. Moreover, intravenous gaseous microspheres with ultrasound have been shown to be a potential alternative to fibrinolytic agents to recanalize discrete peripheral thrombotic arterial occlusions or acute arteriovenous graft thromboses. Small phase I-II randomized and non-randomized clinical trials have shown promising results concerning the potential applications of ultrasound-enhanced thrombolysis in the setting of acute cerebral ischemia. CLOTBUST was an international four-center phase II trial, which demonstrated that, in patients with acute ischemic stroke, transcranial Doppler (TCD) monitoring augments tPA-induced arterial recanalization (sustained complete recanalization rates: 38% vs. 13%) with a non-significant trend toward an increased rate of clinical recovery from stroke, as compared with placebo. The rates of symptomatic intracerebral hemorrhage (sICH) were similar in the active and placebo group (4.8% vs. 4.8%). Smaller single-center clinical trials using transcranial color-coded sonography (TCCD) reported recanalization rates ranging from 27% to 64% and sICH rates of 0-18%. A separate clinical trial evaluating the safety and efficacy of therapeutic low-frequency ultrasound was discontinued because of a concerning sICH rate of 36% in the active group. To further enhance the ability of tPA to break up thrombi, current ongoing clinical trials include phase II studies of a single beam 2 MHz TCD with perflutren-lipid microspheres. Moreover, potential enhancement of intra-arterial tPA delivery is being clinically tested with 1.7-2.1 MHz pulsed wave ultrasound (EKOS catheter) in ongoing phase II-III clinical trials. Intravenous platelet-targeted microbubbles with low-frequency ultrasound are currently investigated as a rapid noninvasive technique to identify thrombosed intracranial and peripheral vessels. Multi-national dose escalation studies of microspheres and the development of an operator independent ultrasound device are underway.

摘要

体外和动物研究表明,静脉注射组织型纤溶酶原激活剂(tPA)进行溶栓时,超声可增强其效果。超声向血栓传递机械压力波,从而使更多血栓表面暴露于循环药物中。此外,超声联合静脉注射气态微球已被证明是一种潜在的替代溶栓剂的方法,可使离散的外周血栓性动脉闭塞或急性动静脉移植物血栓再通。小型I-II期随机和非随机临床试验显示,超声增强溶栓在急性脑缺血中的潜在应用前景良好。CLOTBUST是一项国际多中心II期试验,该试验表明,在急性缺血性中风患者中,经颅多普勒(TCD)监测可增强tPA诱导的动脉再通(持续完全再通率:38%对13%),与安慰剂相比,中风临床恢复率有增加趋势,但无统计学意义。有症状的脑出血(sICH)发生率在活性药物组和安慰剂组相似(4.8%对4.8%)。使用经颅彩色编码超声(TCCD)的较小单中心临床试验报告的再通率为27%至64%,sICH发生率为0%至18%。一项评估治疗性低频超声安全性和有效性的单独临床试验因活性药物组令人担忧的36%的sICH发生率而停止。为了进一步增强tPA分解血栓的能力,目前正在进行的临床试验包括一项使用全氟三丙胺脂质微球的单束2MHz TCD的II期研究。此外,在正在进行的II-III期临床试验中,正在对1.7-2.1MHz脉冲波超声(EKOS导管)增强动脉内tPA递送的潜力进行临床测试。目前正在研究静脉注射血小板靶向微泡联合低频超声作为一种快速无创技术来识别颅内和外周血栓形成的血管。正在进行微球的多国剂量递增研究以及开发一种独立于操作者的超声设备。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验